Skip to main content
Premium Trial:

Request an Annual Quote

Theradiag Acquires miRNA Firm Prestizia

NEW YORK (GenomeWeb News) – French theranostics and in vitro diagnostics company Theradiag announced today it is acquiring biotech firm Prestizia for an undisclosed amount.

Prestizia, a subsidiary of the Holding Incubatrice Biotechnology and Pharmacy, develops microRNA technology and holds the license to IP for a method of characterizing HIV cell tropism. Based on the identification of miRNA signatures, Prestizia's technology could have a number of clinical applications, such as the identification of patients who may benefit from treatments for viral diseases including HIV or differentiating cancer tumor types, Theradiag said.

In collaboration with the Institute de Genetique Moleculaire de Montpelier, Prestizia is developing the first application for its platform, a molecular test of HIV tropism. Theradiag said it is working with the platform to develop new theranostic tests for various indications such as cancer and autoimmune diseases.

"There is a strong synergy between Theradiag and Prestizia and we are delighted with this acquisition that brings Theradiag a research team with state-of-the-art microRNA expertise, as well as an innovative technological platform, which can predict the efficiency of drugs on diseases such as AIDS and cancer," Jean-Jacques Bertrand, chairman of the Holding Incubatrice Biotechnology and Pharmacy, said in a statement.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.